Endoscopy in Inflammatory Bowel Disease DR. REENA KHANNA

Size: px
Start display at page:

Download "Endoscopy in Inflammatory Bowel Disease DR. REENA KHANNA"

Transcription

1 Endoscopy in Inflammatory Bowel Disease DR. REENA KHANNA ASSISTANT PROFESSOR, UNIVERSITY OF WESTERN ONTARIO

2 Background Clinical trials in ulcerative colitis and Crohn s disease require validated instruments to determine disease activity Endoscopy is a relatively objective measure of inflammation Central reading of videos allows blinded, standardized assessment

3 Background: Endoscopic Indices EI are currently used as gold standard for inclusion into clinical trials and to assess outcome Endoscopy is rater-dependent and poor agreement can be a limitation to clinician based instruments NOTE: none of the instruments currently used have been fully validated

4 Endoscopic Scoring Indices for Evaluation of Disease Activity in Ulcerative Colitis Mayo Score Baron Score UCEIS

5 Mayo Mayo Score = 0 Mayo Score = 1 Mayo Score = 2 Mayo Score = 3 Normal or Inactive Disease Mild Disease (erythema, decreased vascular pattern, mild friability) Moderate disease (marked erythema, absent vascular pattern, friability, erosions) Severe disease (spontaneous bleeding, ulceration)

6 Modified Mayo Modified Mayo Endoscopic Sub-score 0 Normal or inactive disease 1 Mild disease (erythema, decreased vascular pattern) 2 Moderate disease (marked erythema, absent vascular pattern, any friability, erosions) 3 Severe disease (spontaneous bleeding, ulceration) Note the difference between Mayo and Modified Mayo: friability (score 1 and score 2). Any friability is considered as 2.

7 Baron

8 Modified Baron Modified Baron Endoscopic Grading for Assessment of Disease Activity 0 Normal mucosa 1 Granular mucosa with an abnormal vascular pattern 2 Friable mucosa 3 Microulceration of the mucosa with spontaneous bleeding 4 Denuded mucosa (gross ulceration) Note the difference between Baron and Modified Baron (not only are friability and spontaneous bleeding are taken into account, but ulceration also)

9 UCEIS Descriptor (Score most severe lesions) Vascular Pattern Score Likert scale anchor points Definition 1 Normal Normal vascular pattern with arborisation of capillaries clearly defined, or with blurring or patchy loss of capillary margins 2 Patchy obliteration Patchy obliteration of vascular pattern 3 Obliterated Complete obliteration of vascular pattern 1 None No visible blood Bleeding Erosions and Ulcers 2 Mucosal Some spots or streaks of coagulated blood on the surface of the mucosa ahead of the scope, which can be washed away 3 Luminal Mild Some free liquid blood in the lumen 4 Luminal moderate or severe Frank blood in the lumen ahead of endoscope or visible oozing from mucosa after washing intraluminal blood, or visible oozing from a haemorrhagic mucosa 1 None Normal mucosa, no visible erosions or ulcers 2 Erosions Tiny (< 5mm) defects in the mucosa of a white or yellow colour with a flat edge 3 Superficial ulcer Large (2-5 mm) defects in the mucosa which are discrete fibrincovered ulcers in comparison with erosions but remains superficial 4 Deep ulcer Deeper excavated defects in the mucosa with a slightly raised edge Comments

10 Definitions Vascular Pattern branching blood vessels visible through the mucosa. Can be normal or abnormal (patchy or complete obliteration). Normal normal vascular pattern with arborisation of capillaries clearly defined, or with blurring or patchy loss of capillary margins Patchy Obliteration patchy obliteration of vascular pattern Obliterated complete obliteration of vascular pattern

11 Bleeding (intestinal) Leak of blood from intestinal blood vessels. None no visible blood Mucosal some spots or streaks of coagulated blood on the surface of the mucosa ahead of the endoscope, which can be washed away Luminal mild some free liquid blood in the lumen Luminal moderate or severe frank blood in the lumen ahead of endoscope or visible oozing from mucosa after washing intraluminal blood, or visible oozing from a haemorrhagic mucosa

12 Erosions and Ulcers a patch of the tissue that is discontinuous with the surrounding tissue because the tissue has decayed or died. Superficial ulcer a large (2-5mm) defect in the mucosa which is a discrete fibrin-covered ulcer in comparison with an erosion but remains superficial Deep ulcer deeper excavated defect in the mucosa with a slightly raised edge

13 Additional Examples of Endoscopic Descriptors Normal (note normal vascular pattern, no erythema, no erosions, no ulcers, no bleeding) Decreased vascular pattern Absent vascular pattern Erosions (< 5mm) Ulcer (> 5mm) Ulceration

14 Examples of Endoscopic Descriptors Friability Spontaneous bleeding

15 Cochrane Review: Endoscopic Scoring Indices for Evaluation of Disease Activity in Ulcerative Colitis Mosli M, Samaan M, Nelson S, et al.

16 5892 records identified 21 records from other sources 2996 records after duplicates removed 2996 records screened 2996 records excluded 27 full text articles assessed 13 records excluded with reasons 14 reports of 9 scoring systems included 9 validated or partially validated indices out of 33 indices

17 Scoring index Validity Reliability Responsiveness Feasibility Content validity Criterion validity Construct validity Inter Intra TR IC 1 Frøslie Endoscopic + +??????? Score 2 Baron Score ?? +?? 3 Mayo Endoscopic +? + + +???? Sub-Score 4 Jeroen Score +?? +?? +?? 5 Endoscopic Activity +? +?????? Index (EAI) 6 Ulcerative Colitis Colonoscopic Index of Severity (UCCIS) 7 Modified 6-point +? + +????? Activity Index ???? +? + + +?? +? 8 Ulcerative Colitis Endoscopic Index of Severity (UCEIS) 9 Matt s Grade +? + + +???? + positive rating? no information or unclear rating - negative rating Inter = interrater Intra = intrarater TR = test-retest IC = internal consistency

18 Cochrane Review: Endoscopic Scoring Indices for Evaluation of Disease Activity in Crohn s Disease Khanna R, Feagan BG, D Haens G

19 4327 records identified 7 records from other sources 3039 records after duplicates removed 3039 records screened 2984 records excluded 55 full text articles assessed 10 records excluded with reasons 45 reports of 2 scoring systems included 2 validated or partially validated indices out of 2 indices

20 Scoring Index Validity Reliability Responsiveness Feasibility Content validity Criterion validity Construct validity Inter Intra TR IC 1 CDEIS 2 SES-CD ?? +?? ?? +? * Rutgeerts Score (post-operative recurrence) not included in this systematic review + positive rating? no information or unclear rating - negative rating Inter = inter-rater Intra = intra-rater TR = test-retest IC = internal consistency

21 Scoring Systems CDEIS SES-CD

22 Sources of Disagreement Lesions between segments/ anastomosis Anal lesions Superficial ulcers Stenosis

23 Conclusions

24 Case 2: Endoscopy 72 year old female Bloody diarrhea 5 times daily Colonoscopy showed mild ulcerative pancolitis Achieved remission on oral 5-ASA 2.4g/day Increasing symptoms for 3 months No benefit from 5-ASA 4.8 g/day and 4 g enemas nightly Colonoscopy showed severe colitis Partial response to prednisone

25 Case 2: Endoscopy Treated with vedolizumab + MTX and achieved clinical remission Colonoscopy showed improvement but not complete mucosal healing Mayo Score: 2

Op#mizing)Management)in)IBD:) Mucosal)Healing)

Op#mizing)Management)in)IBD:) Mucosal)Healing) Op#mizing)Management)in)IBD:) Mucosal)Healing) Vipul&Jairath&MD&PhD& Associate&Professor&of&Medicine,&Epidemiology&and& Biosta=s=cs& Western&University&&& Division&of&Gastroenterology,&& London&Health&Sciences&Network&

More information

IBD scoring systems. Lara Hart, MD FRCPC 1,2 Talat Bessissow, MD FRCPC 1 Mallory Chavannes, MD FRCPC 3,4

IBD scoring systems. Lara Hart, MD FRCPC 1,2 Talat Bessissow, MD FRCPC 1 Mallory Chavannes, MD FRCPC 3,4 IBD scoring systems Lara Hart, MD FRCPC 1,2 Talat Bessissow, MD FRCPC 1 Mallory Chavannes, MD FRCPC 3,4 1. McGill University Health Center, Montreal QC; 2. McMaster University Medical Center, Hamilton

More information

Mucosal healing: does it really matter?

Mucosal healing: does it really matter? Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does

More information

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract

More information

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy

More information

Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels

Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels Authors Makoto Naganuma 1, 2, Naohisa Yahagi 3,RiekoBessho 1, Keiko Ohno 1, Mari Arai 1, Makoto

More information

Clinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis

Clinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 192794, 6 pages http://dx.doi.org/10.1155/2013/192794 Clinical Study Clinical Study of the Relation between

More information

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained

More information

Narrow band imaging efficiency in evaluation of mucosal healing/ relapse of ulcerative colitis

Narrow band imaging efficiency in evaluation of mucosal healing/ relapse of ulcerative colitis Original article Narrow band imaging efficiency in evaluation of mucosal healing/ relapse of ulcerative colitis Authors Seiko Sasanuma 1, Kazuo Ohtsuka 1, 2, Shin-ei Kudo 1, Noriyuki Ogata 1, Yasuharu

More information

Title: Author: Journal:

Title: Author: Journal: IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution

More information

Controversies in IBD: Resolving clinical dilemmas using Cochrane reviews

Controversies in IBD: Resolving clinical dilemmas using Cochrane reviews Controversies in IBD: Resolving clinical dilemmas using Cochrane reviews DR. NILESH CHANDE COORDINATING EDITOR, IBD REVIEW GROUP; UNIVERSITY OF WESTERN ONTARIO, LONDON, ON CANADA An international organisation

More information

Endoscopy in IBD. F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M.

Endoscopy in IBD. F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M. F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M. F.Hartmann@em.uni-frankfurt.de Indications for endoscopy Diagnosis Management Surveillance Diagnosis Single most valuable tool: ileocolonoscopy

More information

Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases

Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases Parakkal Deepak, M.B.B.S., M.S. Assistant Professor of Medicine Division of Gastroenterology John T. Milliken Department

More information

Medical Management of Inflammatory Bowel Disease

Medical Management of Inflammatory Bowel Disease Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,

More information

What do we need for diagnosis of IBD

What do we need for diagnosis of IBD What do we need for diagnosis of IBD Kaichun Wu Dept. of Gastroenterology, Xijing Hospital Fourth Military Medical University Xi an an,, China In China UC 11.6/10 5,CD 1.4/10 5 Major cause of chronic diarrhea

More information

Withdrawal of drug therapy in patients with quiescent Crohn s disease

Withdrawal of drug therapy in patients with quiescent Crohn s disease Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy

More information

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel

More information

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel

More information

As clinicians we would all agree that the goal for our

As clinicians we would all agree that the goal for our CURRENT CONTROVERSIES: PRO, CON, AND BALANCE Controversies in Mucosal Healing in Ulcerative Colitis Sunanda Kane, MD,* Frances Lu, MD, Asher Kornbluth, MD, Dahlia Awais, MD, and Peter D.R. Higgins, MD,

More information

Activity and Endoscopic measures : Crohn s disease. Jean-Frederic COLOMBEL Justin Cote-Daigneault Icahn Medical School at Mount Sinai, New York

Activity and Endoscopic measures : Crohn s disease. Jean-Frederic COLOMBEL Justin Cote-Daigneault Icahn Medical School at Mount Sinai, New York Activity and Endoscopic measures : Crohn s disease Jean-Frederic COLOMBEL Justin Cote-Daigneault Icahn Medical School at Mount Sinai, New York J-F Colombel has served as consultant or advisory board member

More information

The Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.

The Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D. The Spectrum of IBD Inflammatory Bowel Disease Fernando Vega, M.D. Epidemiology CD and UC together 1:400 UC Prevalence 1:500 UC Incidence 6-12K/annum CD Prevalence 1:1000 CD Incidence 3-6K/annum Symptoms

More information

Chromoendoscopy as an Adjunct to Colonoscopy

Chromoendoscopy as an Adjunct to Colonoscopy Chromoendoscopy as an Adjunct to Colonoscopy Policy Number: 2.01.84 Last Review: 1/2018 Origination: 7/2017 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide

More information

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:

More information

Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis

Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis Alimentary Pharmacology and Therapeutics Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis G. R. Lichtenstein*,

More information

Endpoints for Stopping Treatment in UC

Endpoints for Stopping Treatment in UC Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh

More information

Implementation of disease and safety predictors during disease management in UC

Implementation of disease and safety predictors during disease management in UC Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male

More information

Case History B Female patient 1970 Clinical History : crampy abdominal pain and episodes of bloody diarrhea Surgical treatment

Case History B Female patient 1970 Clinical History : crampy abdominal pain and episodes of bloody diarrhea Surgical treatment Case History B-1325945 Female patient 1970 Clinical History : crampy abdominal pain and episodes of bloody diarrhea Surgical treatment Case History B-1325945 Pathology Submucosa & Muscularis Endometriosis

More information

ENTYVIO (VEDOLIZUMAB)

ENTYVIO (VEDOLIZUMAB) ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...

More information

Endoscopic monitoring of IBD patients for healing and dysplasia in 2018

Endoscopic monitoring of IBD patients for healing and dysplasia in 2018 Endoscopic monitoring of IBD patients for healing and dysplasia in 2018 Marietta Iacucci, MD, PhD, FASGE Senior Associate Professor(Reader) University of Birmingham, UK Adjunct Associate Professor of Medicine

More information

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University

More information

Disease Monitoring. Symptoms Activity. No Symptoms No Activity. What is the Problem with Dogma? What are the FACTS

Disease Monitoring. Symptoms Activity. No Symptoms No Activity. What is the Problem with Dogma? What are the FACTS Heal the Mucosa or Heal the Patient (Data vs Dogma) Heal the Mucosa Cary G. Sauer MD MSCR Associate Professor, Emory University School of Medicine Clinical Director, IBD Program The Facts vs The Force

More information

ENTYVIO (VEDOLIZUMAB)

ENTYVIO (VEDOLIZUMAB) ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...

More information

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS SURGICAL MANAGEMENT OF ULCERATIVE COLITIS Cary B. Aarons, MD Associate Professor of Surgery Division of Colon & Rectal Surgery University of Pennsylvania AGENDA Background Diagnosis/Work-up Medical Management

More information

How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases?

How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases? How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases? Alessandro Armuzzi Lead IBD Unit Complesso Integrato Columbus Fondazione Policlinico Gemelli Università

More information

Treating Crohn s and Colitis in the ASC

Treating Crohn s and Colitis in the ASC Treating Crohn s and Colitis in the ASC Kimberly M Persley, MD Texas Digestive Disease consultants TASC Meeting Outline IBD 101 Diagnosis Treatment Burden of Disease Role of ASC Inflammatory Bowel Disease

More information

Management of Moderate to Severe Ulcerative Colitis

Management of Moderate to Severe Ulcerative Colitis Management of Moderate to Severe Ulcerative Colitis Neilanjan Nandi, MD Assistant Professor of Medicine Associate Program Director Division of Gastroenterology Drexel University College of Medicine Hahnemann

More information

Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France

Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments

More information

Crohn s Disease. Resident Lecture 1/17/19

Crohn s Disease. Resident Lecture 1/17/19 Crohn s Disease Resident Lecture 1/17/19 Objectives Features/Classification of Crohn s Disease Medical Treatment Surgical Indications Surgical Considerations 2 Case 25 yo F presents to your office with

More information

A Case of Crohn s Disease with Mesalazine Allergy that was Difficult to Differentiate from Comorbid Ulcerative Colitis

A Case of Crohn s Disease with Mesalazine Allergy that was Difficult to Differentiate from Comorbid Ulcerative Colitis doi: 10.2169/internalmedicine.1607-18 http://internmed.jp CASE REPORT A Case of Crohn s Disease with Mesalazine Allergy that was Difficult to Differentiate from Comorbid Ulcerative Colitis Rumiko Tsuboi,

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,

More information

Author's response to reviews

Author's response to reviews Author's response to reviews Title: Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis Authors: Dr Thomas de Lange (t.d.lange@ioks.uio.no) Stig Larsen (stig.larsen@veths.no)

More information

Historical perspective

Historical perspective Raj Santharam, MD GI Associates, LLC Clinical Assistant Professor of Medicine Medical College of Wisconsin Historical perspective FFS first widespread use in the early 1970 s Expansion of therapeutic techniques

More information

BMC Gastroenterology. Open Access. Abstract. BioMed Central

BMC Gastroenterology. Open Access. Abstract. BioMed Central BMC Gastroenterology BioMed Central Research article Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis Thomas de Lange* 1, Stig Larsen 2 and Lars Aabakken 3 Open Access

More information

Fujiya M, Saitoh Y, Watari J, Moriichi K, Kohgo Y.

Fujiya M, Saitoh Y, Watari J, Moriichi K, Kohgo Y. Digestive Endoscopy (2007) 19(s1):S145-S149. Auto-Fluorescence Imaging is useful to assess the activity of ulcerative colitis Fujiya M, Saitoh Y, Watari J, Moriichi K, Kohgo Y. Auto-Fluorescence Imaging

More information

Differential Diagnosis of Inflammatory Bowel Disease: What Is the Role of Colonoscopy?

Differential Diagnosis of Inflammatory Bowel Disease: What Is the Role of Colonoscopy? REVIEW Clin Endosc 2012;45:254-262 Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2012.45.3.254 Open Access Differential Diagnosis of Inflammatory Bowel Disease: What Is the

More information

What is ulcerative colitis?

What is ulcerative colitis? What is ulcerative colitis? Ulcerative colitis is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. Ulcers form where inflammation has killed the cells

More information

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital Aims To understand the aetiology of IBD To understand the impact that

More information

Supplementary Table 1: Simple Clinical Colitis Activity Index (SCCAI)

Supplementary Table 1: Simple Clinical Colitis Activity Index (SCCAI) Supplementary Table : Simple Clinical Colitis Activity Index (SCCAI) Descriptor Description Score Bowel frequency (day) Bowel frequency (night) Urgency of defecation Blood in stool General well being Extracolonic

More information

Patient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know?

Patient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know? Patient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know? Peter D.R. Higgins Director, IBD Program University of Michigan What are PROs? ClinRO Patient- Reported

More information

ד"ר דוד ירדני המכון לגסטרואנטרולוגיה ומחלות כבד מרכז רפואי סורוקה

דר דוד ירדני המכון לגסטרואנטרולוגיה ומחלות כבד מרכז רפואי סורוקה ד"ר דוד ירדני המכון לגסטרואנטרולוגיה ומחלות כבד מרכז רפואי סורוקה Presentaion: S.A is 38 years old. Referred for rectal bleeding investigation. Describes several occasions of bleeding and abdominal pain.

More information

Mohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University.

Mohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University. Mohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University. Chronic transmural inflammatory process of the bowel & affects any part of the gastro -intestinal tract from the mouth to the

More information

Biologic Therapy for Ulcerative Colitis in 2015

Biologic Therapy for Ulcerative Colitis in 2015 5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58

More information

Bleeding in the Digestive Tract

Bleeding in the Digestive Tract Bleeding in the Digestive Tract National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH U.S. Department of Health

More information

Early Mucosal Healing With Infliximab Is Associated With Improved Longterm Clinical Outcomes in Ulcerative Colitis

Early Mucosal Healing With Infliximab Is Associated With Improved Longterm Clinical Outcomes in Ulcerative Colitis GASTROENTEROLOGY 2011;141:1194 1201 Early Mucosal Healing With Infliximab Is Associated With Improved Longterm Clinical Outcomes in Ulcerative Colitis JEAN FRÉDÉRIC COLOMBEL,* PAUL RUTGEERTS, WALTER REINISCH,

More information

Does Fecal Microbiota Transplantation Cause Clinical Remission in Patients with Ulcerative Colitis?

Does Fecal Microbiota Transplantation Cause Clinical Remission in Patients with Ulcerative Colitis? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2017 Does Fecal Microbiota Transplantation

More information

Moderately to severely active ulcerative colitis

Moderately to severely active ulcerative colitis Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients

More information

Title: Accuracy of calprotectin in evaluating sub- clinical inflammation in Ulcerative

Title: Accuracy of calprotectin in evaluating sub- clinical inflammation in Ulcerative PROTOCOL ACERTIVE STUDY Title: Accuracy of calprotectin in evaluating sub- clinical inflammation in Ulcerative colitis (ACERTIVE) Sponsor: Portuguese IBD Study Group (Grupo de Estudos da Doença Inflamatória

More information

Case Report Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent

Case Report Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent Gastroenterology Research and Practice Volume 2010, Article ID 860394, 4 pages doi:10.1155/2010/860394 Case Report Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent Jessica

More information

Pouchitis and Cuffitis A bloody mess. Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board

Pouchitis and Cuffitis A bloody mess. Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board Pouchitis and Cuffitis A bloody mess Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board Ileal-pouch anal anastomosis https://www.pennmedicine.org/for-health-care-professionals/for-physicians/physician-education-and-resources/clinicalbriefings/2018/february/total-proctocolectomy-with-jpouch-reconstruction-for-ulcerative-colitis

More information

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight

More information

... Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment.

... Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment. Definition Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment. " Epidemiology Humans represent the main reservoir of Clostridium difficile, which is not part of the

More information

Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease

Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease REVIEW Clin Endosc 2016;49:370-375 http://dx.doi.org/10.5946/ce.2016.090 Print ISSN 2234-2400 On-line ISSN 2234-2443 Open Access Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease Ji

More information

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence

More information

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014 Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn

More information

CLINICAL INSIGHTS 01

CLINICAL INSIGHTS 01 P2 Borrowing a Treatment Paradigm From Rheumatoid Arthritis P4 Antidrug Antibody Monitoring in Practice P6 Proactive Drug Monitoring Informs Therapeutic Dose Adjustments P7 Keeping Patients in Remission

More information

Naltrexone for the treatment of Crohn s disease

Naltrexone for the treatment of Crohn s disease Naltrexone for the treatment of Crohn s disease DR. NILESH CHANDE COORDINATING EDITOR, IBD REVIEW GROUP; UNIVERSITY OF WESTERN ONTARIO, LONDON, ON CANADA Opioid receptors 3 major types kappa κ delta δ

More information

ENTYVIO (VEDOLIZUMAB)

ENTYVIO (VEDOLIZUMAB) ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 285.8 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...

More information

WHAT IS ULCERATIVE COLITIS?

WHAT IS ULCERATIVE COLITIS? 235 60th Street, West New York, NJ 07093 T: (201) 854-4646 F: (201) 854-4647 810 Main Street, Hackensack, NJ 07601 T: (201) 488-0095 Ulcerative Colitis WHAT IS ULCERATIVE COLITIS? Ulcerative colitis is

More information

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation ORIGINAL ARTICLE Annals of Gastroenterology (2019) 32, 1-6 Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation Dimitrios S. Politis a, Konstantinos

More information

What Every Pathologist Wants the GI Nurse to Know (and how you can help us help you)

What Every Pathologist Wants the GI Nurse to Know (and how you can help us help you) What Every Pathologist Wants the GI Nurse to Know (and how you can help us help you) Jonathan N. Glickman MD PhD Director, GI Pathology, Caris Diagnostics, Newton, MA Associate Professor of Pathology,

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant

More information

Gionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico

Gionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways

More information

Achieving Success in Ulcerative Colitis: the Role of Infliximab

Achieving Success in Ulcerative Colitis: the Role of Infliximab Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis

More information

Chromoendoscopy - Should It Be Standard of Care in IBD?

Chromoendoscopy - Should It Be Standard of Care in IBD? Chromoendoscopy - Should It Be Standard of Care in IBD? John F. Valentine, MD, FACG Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Utah What is the point of

More information

3/20/2009. Julio Garcia-Aguilar Chair, Department of Surgery City of Hope, Duarte, California

3/20/2009. Julio Garcia-Aguilar Chair, Department of Surgery City of Hope, Duarte, California Ischemic Colitis Ischemic Colitis Julio Garcia-Aguilar Chair, Department of Surgery City of Hope, Duarte, California Ischemic colitis (IC) represents greater than 50% of all intestinal ischemia IC most

More information

The Paris classification of colonic lesions

The Paris classification of colonic lesions The Paris classification of colonic lesions Training to improve the interobserver agreement among international experts Sascha van Doorn, MD, PhD-student in CRC-reserach group of Evelien Dekker Introduction

More information

Quality Measures In Colonoscopy: Why Should I Care?

Quality Measures In Colonoscopy: Why Should I Care? Quality Measures In Colonoscopy: Why Should I Care? David Greenwald, MD, FASGE Professor of Clinical Medicine Albert Einstein College of Medicine Montefiore Medical Center Bronx, New York ACG/ASGE Best

More information

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD 5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED

More information

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

CCFA. Crohns Disease vs UC: What is the best treatment for me? November CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York

More information

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:

More information

September 12, 2015 Millie D. Long MD, MPH, FACG

September 12, 2015 Millie D. Long MD, MPH, FACG Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn

More information

Deep Enteroscopy Methods to Diagnose Small Bowel IBD

Deep Enteroscopy Methods to Diagnose Small Bowel IBD Deep Enteroscopy Methods to Diagnose Small Bowel IBD Name: Institution: Peter Draganov University of Florida, Gainesville, FL Overview Types of enteroscopy Enteroscopy equipment Enetoscopy do and don'ts

More information

Pitfalls in the Diagnosis of Inflammatory Bowel Disease

Pitfalls in the Diagnosis of Inflammatory Bowel Disease Pitfalls in the Diagnosis of Inflammatory Bowel Disease Robert H Riddell MD Mt Sinai Hospital Toronto Prof of Lab. Medicine and Pathobiology University of Toronto Atypical gross / endoscopic distribution

More information

5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA

5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA 5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA Background RCTs investigating the efficacy of aminosalicylates for

More information

Positioning New Therapies

Positioning New Therapies Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed

More information

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center

More information

AVX-470, an Orally Delivered Anti-TNF Antibody for Treatment of Acute Ulcerative Colitis: Results of a First-in- Human Trial

AVX-470, an Orally Delivered Anti-TNF Antibody for Treatment of Acute Ulcerative Colitis: Results of a First-in- Human Trial AVX-470, an Orally Delivered Anti-TNF Antibody for Treatment of Acute Ulcerative Colitis: Results of a First-in- Human Trial M Scott Harris 1, Deborah Hartman 1, Sharon Spence 1, Sally Kennedy 1, Theodore

More information

Endoscopic Mucosal Resection (EMR) & Endoscopic Submucosal Dissection (ESD)

Endoscopic Mucosal Resection (EMR) & Endoscopic Submucosal Dissection (ESD) Endoscopic Mucosal Resection (EMR) & Endoscopic Submucosal Dissection (ESD) Minimally Invasive Polyp Removal IE-02700-Understanding EMR and ESD Brochure_R3.indd 1 Occasionally, a polyp that infiltrates

More information

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly

More information

Persistence of mucosal abnormality in ulcerative colitis

Persistence of mucosal abnormality in ulcerative colitis Gut, 966, 7, 55 Persistence of mucosal abnormality in ulcerative colitis A. P. DICK, L. P. HOLT', AND E. R. DALTON rom Addenbrooke's Hospital, Cambridge, and the Department of Human Ecology, University

More information

Ulcerative colitis (UC) is a. The Patient with Newly Diagnosed Ulcerative Colitis: Anticipating the Questions and Individualizing the Answers

Ulcerative colitis (UC) is a. The Patient with Newly Diagnosed Ulcerative Colitis: Anticipating the Questions and Individualizing the Answers The Patient with Newly Diagnosed Ulcerative Colitis: Anticipating the Questions and Individualizing the Answers James Gregor, MD, Division of Gastroenterology, The University of Western Ontario, London,

More information

BENEFIT APPLICATION BLUE CARD/NATIONAL ACCOUNT ISSUES

BENEFIT APPLICATION BLUE CARD/NATIONAL ACCOUNT ISSUES Medical Policy BCBSA Ref. Policy: 2.01.84 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 2.01.87 Confocal Laser Endomicroscopy 6.01.32 Virtual Colonoscopy/Computed

More information

What is Crohn's disease?

What is Crohn's disease? What is Crohn's disease? Crohn's disease is a chronic inflammatory disorder that causes inflammation of the digestive tract. It can affect any area of the GI tract, from the mouth to the anus, but it most

More information

Colon Polyps: Detection, Inspection and Characteristics

Colon Polyps: Detection, Inspection and Characteristics Colon Polyps: Detection, Inspection and Characteristics Stephen Kim, M.D. Assistant Professor of Medicine Interventional Endoscopy Services UCLA Division of Digestive Diseases September 29, 2018 1 Disclosures

More information

vedolizumab (Entyvio )

vedolizumab (Entyvio ) vedolizumab (Entyvio ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ),

More information

Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων

Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that

More information

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic

More information

Filiform polyposis of ulcerative colitis

Filiform polyposis of ulcerative colitis Filiform polyposis of ulcerative colitis Authors: Keisuke Yamada, Hironori Samura, Tatsuya Kinjo, Tetsu Kinjo, Akira Hokama, Jiro Fujita Article type: Clinical image Received: December 7, 2018. Accepted:

More information

Patho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology

Patho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology Patho Basic Chronic Inflammatory Bowel Diseases Jürg Vosbeck Pathology General Group of chronic relapsing diseases with chronic bloody or watery diarrhea Usually ulcerative colitis (UC) or Crohn s disease

More information

Before Endoscopy? Indications Thermal Coagulation Injection Therapy Combination Therapy Fibrin Sealant Endoclips Argon Plasma Coagulation Lysine -

Before Endoscopy? Indications Thermal Coagulation Injection Therapy Combination Therapy Fibrin Sealant Endoclips Argon Plasma Coagulation Lysine - Dr Simon Smale Before Endoscopy? Indications Thermal Coagulation Injection Therapy Combination Therapy Fibrin Sealant Endoclips Argon Plasma Coagulation Lysine - Haemmostop Variceal Banding Histoacryl

More information